Diabetes Care, Vol 21, Issue 11 1897-1903, Copyright © 1998 by American Diabetes Association

ARTICLES

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes

RB Goldberg, D Einhorn, CP Lucas, MS Rendell, P Damsbo, WC Huang, P Strange and RG Brodows
Diabetes Research Institute, University of Miami School of Medicine, Florida 33136, USA.

OBJECTIVE: The objective of the study was to assess the efficacy and safety of repaglinide compared with placebo in the treatment of patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: This was a phase II multicenter, double-blind, placebo-controlled, randomized, dose-adjustment and maintenance trial. After screening and a 2-week washout period, 99 patients were randomized to receive either repaglinide (n = 66) or placebo (n = 33). Patients underwent 6 weeks of dose adjustment followed by 12 weeks of dose maintenance. Fasting and stimulated glycosylated hemoglobin (HbA1c), plasma glucose, insulin, and C-peptide were measured at predetermined intervals. Adverse events and hypoglycemic episodes were recorded. RESULTS: From baseline to last visit, mean HbA1c decreased from 8.5 to 7.8% in patients treated with repaglinide and increased from 8.1 to 9.3% in patients receiving placebo, with a statistically significant difference of - 1.7% (P < 0.0001) between treatment groups at the last visit. Mean fasting plasma glucose and postprandial glucose increased in patients receiving placebo and decreased in patients treated with repaglinide, with statistically significant (P < 0.01) differences between groups at the last visit. Concentrations of fasting and postprandial insulin and C-peptide were lower at the last visit compared with baseline for patients treated with placebo and higher for patients treated with repaglinide, and the differences between groups were statistically significant (P < 0.05). Overall, repaglinide was well tolerated. CONCLUSIONS: This study demonstrated that repaglinide was safe and efficacious in lowering blood glucose concentrations. In addition to overall improvement in glycemic control noted with repaglinide in both sulfonylurea-treated patients and oral hypoglycemic agent-naive patients, repaglinide had a potent glucose-lowering effect in the postprandial period.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Selvin, S. Bolen, H.-C. Yeh, C. Wiley, L. M. Wilson, S. S. Marinopoulos, L. Feldman, J. Vassy, R. Wilson, E. B. Bass, et al. Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review Arch Intern Med, October 27, 2008; 168(19): 2070 - 2080. [Abstract] [Full Text] [PDF]

				B. Kimmel and S. E. Inzucchi Oral Agents for Type 2 Diabetes: An Update Clin. Diabetes, April 1, 2005; 23(2): 64 - 76. [Abstract] [Full Text] [PDF]

				J.-F. Yale Oral Antihyperglycemic Agents and Renal Disease: New Agents, New Concepts J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S7 - S10. [Abstract] [Full Text] [PDF]

				M. J. Abrahamson Optimal Glycemic Control in Type 2 Diabetes Mellitus: Fasting and Postprandial Glucose in Context Arch Intern Med, March 8, 2004; 164(5): 486 - 491. [Abstract] [Full Text] [PDF]

				J. E. Gerich Clinical Significance, Pathogenesis, and Management of Postprandial Hyperglycemia Arch Intern Med, June 9, 2003; 163(11): 1306 - 1316. [Abstract] [Full Text] [PDF]

				J. Davidson Should Postprandial Glucose Be Measured and Treated to a Particular Target? Yes. Diabetes Care, June 1, 2003; 26(6): 1919 - 1921. [Full Text] [PDF]

				M. S. Thomsen, D. Chassard, E. Evene, K. K. Nielsen, and M. Jorgensen Pharmacokinetics of Repaglinide in Healthy Caucasian and Japanese Subjects J. Clin. Pharmacol., January 1, 2003; 43(1): 23 - 28. [Abstract] [Full Text]

				C. G. Parkin and N. Brooks Is Postprandial Glucose Control Important? Is It Practical In Primary Care Settings? Clin. Diabetes, April 1, 2002; 20(2): 71 - 76. [Abstract] [Full Text] [PDF]

				O. Schmitz, S. Lund, P. H. Andersen, M. Jonler, and N. Porksen Optimizing Insulin Secretagogue Therapy in Patients With Type 2 Diabetes: A randomized double-blind study with repaglinide Diabetes Care, February 1, 2002; 25(2): 342 - 346. [Abstract] [Full Text] [PDF]

				S. E. Inzucchi Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review JAMA, January 16, 2002; 287(3): 360 - 372. [Abstract] [Full Text] [PDF]

				M. Saleh and G. Grunberger Hypoglycemia: An Excuse for Poor Glycemic Control? Clin. Diabetes, October 1, 2001; 19(4): 161 - 167. [Abstract] [Full Text] [PDF]

				D. A. de Luis, R. Aller, L. Cuellar, C. Terroba, H. Ovalle, O. Izaola, and E. Romero Effect of Repaglinide Addition to NPH Insulin Monotherapy on Glycemic Control in Patients With Type 2 Diabetes Diabetes Care, October 1, 2001; 24(10): 1844 - 1845. [Full Text] [PDF]

				F. M. Gribble, S. E. Manley, and J. C. Levy Randomized Dose Ranging Study of the Reduction of Fasting and Postprandial Glucose in Type 2 Diabetes by Nateglinide (A-4166) Diabetes Care, July 1, 2001; 24(7): 1221 - 1225. [Abstract] [Full Text] [PDF]

				R. G. Moses, R. Gomis, K. B. Frandsen, J.-L. Schlienger, and I. Dedov Flexible Meal-Related Dosing With Repaglinide Facilitates Glycemic Control in Therapy-Naive Type 2 Diabetes Diabetes Care, January 1, 2001; 24(1): 11 - 15. [Abstract] [Full Text]